1
|
Gettinger S, Schenker M, De Langen J, Fischer J, Morgensztern D, Ciuleanu TE, Beck T, De Castro Carpeno J, Schumann C, Yang X, Telivala B, Deschepper K, Nadal E, Schalper K, Spires T, Balli D, Nassar A, Karam S, Bhingare A, Spigel D. 2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592. Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100107] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
2
|
Padmakar Darne C, Velaparthi U, Saulnier M, Frennesson D, Liu P, Huang A, Tokarski J, Fura A, Spires T, Newitt J, Spires VM, Obermeier MT, Elzinga PA, Gottardis MM, Jayaraman L, Vite GD, Balog A. The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer. Bioorg Med Chem Lett 2022; 75:128951. [PMID: 36031020 DOI: 10.1016/j.bmcl.2022.128951] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2022] [Revised: 08/14/2022] [Accepted: 08/19/2022] [Indexed: 11/18/2022]
Abstract
We report herein, the discovery of BMS-737 (compound 33) as a potent, non-steroidal, reversible small molecule inhibitor demonstrating 11-fold selectivity for CYP17 lyase over CYP17 hydroxylase, as well as a clean xenobiotic CYP profile for the treatment of castration-resistant prostate cancer (CRPC). Extensive SAR studies on the initial lead 1 at three different regions of the molecule resulted in the identification of BMS-737, which demonstrated a robust 83% lowering of testosterone without any significant perturbation of the mineralocorticoid and glucocorticoid levels in cynomologous monkeys in a 1-day PK/PD study.
Collapse
Affiliation(s)
| | - Upender Velaparthi
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States.
| | - Mark Saulnier
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - David Frennesson
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Peiying Liu
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Audris Huang
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - John Tokarski
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Aberra Fura
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Thomas Spires
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - John Newitt
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Vanessa M Spires
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Mary T Obermeier
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Paul A Elzinga
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Marco M Gottardis
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Lata Jayaraman
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Gregory D Vite
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| | - Aaron Balog
- Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543, United States
| |
Collapse
|
3
|
Yang Z, Loy J, Poirson B, Dai Y, Rajendran S, Xu S, Spires V, Gururajan M, Lin Z, Arbanas J, Carl S, Pace S, Wang Y, Mehl J, Vasudevan K, Spires T, Novosiadly R, Coker S, Perez R, Covello K, Morin P, Graziano R, Broz M, Lehman-McKeeman L. Application of Pharmacokinetic/Pharmacodynamic Modeling to Bridge Mouse Antitumor Efficacy and Monkey Toxicology Data for Determining the Therapeutic Index of an Interleukin-10 Fc Fusion Protein. Front Pharmacol 2022; 13:829063. [PMID: 35795558 PMCID: PMC9251408 DOI: 10.3389/fphar.2022.829063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2021] [Accepted: 05/24/2022] [Indexed: 11/13/2022] Open
Abstract
Pharmacokinetic/pharmacodynamic (PK/PD) modeling was performed to quantitatively integrate preclinical pharmacology and toxicology data for determining the therapeutic index (TI) of an interleukin-10 (IL-10) fragment crystallizable (Fc) fusion protein. Mouse Fc fused with mouse IL-10 (mFc-mIL-10) was studied in mice for antitumor efficacy, and the elevation of interleukin-18 (IL-18) was examined as a PD biomarker. The in vivo mFc-mIL-10 EC50 for the IL-18 induction was estimated to be 2.4 nM, similar to the in vitro receptor binding affinity (Kd) of 3.2 nM. The IL-18 induction was further evaluated in cynomolgus monkeys, where the in vivo induction EC50 by a human IL-10 human Fc-fusion protein (hFc-hIL-10) was 0.08 nM vs. 0.3 nM measured as the in vitro Kd. The extent of the IL-18 induction correlated with mouse antitumor efficacy and was used to connect mouse efficacy to that in monkeys. The PD-based efficacious dose projected in monkeys was comparable to the results obtained using a PK-based method in which mouse efficacious exposure was targeted and corrected for affinity differences between the species. Furthermore, PK/PD relationships were developed for anemia and thrombocytopenia in monkeys treated with hFc-hIL-10, with thrombocytopenia predicted to be dose-limiting toxicity. Using quantitative pharmacology and toxicology information obtained through modeling work in the same species, the TI of hFc-hIL-10 in monkeys was determined to be 2.4 (vs. PD-based efficacy) and 1.2–3 (vs. PK-based efficacy), indicating a narrow safety margin. The model-based approaches were proven valuable to the developability assessment of the IL-10 Fc-fusion protein.
Collapse
Affiliation(s)
- Zheng Yang
- Metabolism and Pharmacokinetics, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
- *Correspondence: Zheng Yang,
| | - James Loy
- Discovery Toxicology, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Cambridge, MA, United States
| | - Brian Poirson
- Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States
| | - Yanshan Dai
- Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States
| | - Surendran Rajendran
- Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States
| | - Shihua Xu
- Nonclinical Disposition and Bioanalysis, Bristol Myers Squibb, Princeton, NJ, United States
| | - Vanessa Spires
- Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States
| | - Murali Gururajan
- Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States
| | - Zheng Lin
- Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States
| | - Jaren Arbanas
- Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States
| | - Stephen Carl
- Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
| | - Samantha Pace
- Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
| | - Yun Wang
- Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
| | - John Mehl
- Discovery Pharmaceutics and Analytical Sciences, Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
| | - Krishna Vasudevan
- Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States
| | - Thomas Spires
- Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States
| | - Ruslan Novosiadly
- Translational Medicine, Bristol Myers Squibb, Princeton, NJ, United States
| | - Shodeinde Coker
- Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States
| | - Raymond Perez
- Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States
| | - Kelly Covello
- Oncology Early Clinical Development, Bristol Myers Squibb, Princeton, NJ, United States
| | - Paul Morin
- Discovery Biotherapeutics, Bristol Myers Squibb, Princeton, NJ, United States
| | - Robert Graziano
- Discovery Oncology, Bristol Myers Squibb, Princeton, NJ, United States
| | - Miranda Broz
- Discovery Oncology, Bristol Myers Squibb, Redwood City, CA, United States
| | - Lois Lehman-McKeeman
- Pharmaceutical Candidate Optimization, Bristol Myers Squibb, Princeton, NJ, United States
| |
Collapse
|
4
|
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan M, Talbot T, Monnet I, Hiret S, Baas P, Nowak A, Fujimoto N, Tsao A, Mansfield A, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol 2022; 33:488-499. [DOI: 10.1016/j.annonc.2022.01.074] [Citation(s) in RCA: 16] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Accepted: 01/24/2022] [Indexed: 12/11/2022] Open
|
5
|
Ramalingam S, Balli D, Ciuleanu TE, Pluzanski A, Lee JS, Schenker M, Bernabe Caro R, Lee K, Bartolucci R, Audigier-Valette C, Hellmann M, Paz-Ares L, Reck M, Borghaei H, Brahmer J, O’Byrne K, Tran P, Spires T, Geese W, Agrawal S. 4O Nivolumab (NIVO) + ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced NSCLC (aNSCLC) in CheckMate 227 part 1: Efficacy by KRAS, STK11, and KEAP1 mutation status. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
6
|
Prenner SB, Kumar A, Zhao L, Cvijic ME, Basso M, Spires T, Li Z, Yarde M, Bhattacharya P, Zamani P, Mazurek J, Wang Z, Seiffert D, Gordon DA, Chirinos JA. Effect of Serum Albumin Levels in Patients With Heart Failure With Preserved Ejection Fraction (from the TOPCAT Trial). Am J Cardiol 2020; 125:575-582. [PMID: 31843232 DOI: 10.1016/j.amjcard.2019.11.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 10/31/2019] [Accepted: 11/07/2019] [Indexed: 01/09/2023]
Abstract
Little data are available regarding the determinants and prognostic significance of serum albumin in Heart Failure with Preserved Ejection Fraction (HFpEF). We sought to examine the phenotypic correlates of albumin and its independent prognostic implications in HFpEF. We analyzed data from 3,254 subjects enrolled the TOPCAT trial. We stratified subjects according to tertiles of albumin and examined differences in various phenotypic traits between these strata, including 8 protein biomarkers selected ad hoc and measured from frozen samples available in a subset of participants (n = 372). We also assessed the relationship between albumin and the trial primary endpoint. Lower albumin was associated with older age, black race, and greater prevalence of NYHA class III-IV, peripheral arterial disease, atrial fibrillation and diabetes mellitus. Lower albumin was also associated with increased levels of several inflammatory biomarkers, markers of liver fibrosis, albuminuria, and greater arterial stiffness, diastolic dysfunction and pulmonary hypertension. Albumin was a strong predictor of the primary trial endpoint, even after adjustment for the MAGGIC risk score (hazard ratio [HR] 0.72, confidence interval [CI] 0.67 to 0.78; p <0.0001) and prespecified traditional risk factors (HR 0.78, CI 0.71 to 0.85; p <0.0001). Lower albumin was strongly associated with a worse prognosis even well within normal ranges (>3.5 g/dL), with a sharp increase in risk between 4.6 and 3.6 g/dL. In conclusion, albumin is an integrated marker of various adverse processes in HFpEF, including inflammation, subclinical liver disease, arterial stiffness, and renal disease. Albumin is a powerful risk predictor independent of traditional risk prediction models, even within normal ranges.
Collapse
|
7
|
Caetano MS, Younes AI, Barsoumian HB, Quigley M, Menon H, Gao C, Spires T, Reilly TP, Cadena AP, Cushman TR, Schoenhals JE, Li A, Nguyen QN, Cortez MA, Welsh JW. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res 2019; 25:7576-7584. [PMID: 31540976 DOI: 10.1158/1078-0432.ccr-19-0795] [Citation(s) in RCA: 42] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2019] [Revised: 07/10/2019] [Accepted: 09/17/2019] [Indexed: 01/07/2023]
Abstract
PURPOSE Radiotherapy (RT) traditionally has been used for local tumor control in the treatment of cancer. The recent discovery that radiotherapy can have anticancer effects on the immune system has led to recognition of its ability to sensitize the tumor microenvironment to immunotherapy. However, radiation can also prompt adverse immunosuppressive effects that block aspects of systemic response at other tumor sites. Our hypothesis was that inhibition of the MER proto-oncogene tyrosine kinase (MerTK) in combination with anti-programmed cell death-1 (α-PD1) checkpoint blockade will enhance immune-mediated responses to radiotherapy. EXPERIMENTAL DESIGN We tested the efficacy of this triple therapy (Radiation + α-PD1 + α-MerTK mAbs) in 129Sv/Ev mice with bilateral lung adenocarcinoma xenografts. Primary tumors were treated with stereotactic radiotherapy (36 Gy in 3 12-Gy fractions), and tumors were monitored for response. RESULTS The triple therapy significantly delayed abscopal tumor growth, improved survival rates, and reduced numbers of lung metastases. We further found that the triple therapy increased the activated CD8+ and NK cells populations measured by granzyme B expression with upregulation of CD8+CD103+ tissue-resident memory cells (TRM) within the abscopal tumor microenvironment relative to radiation only. CONCLUSIONS The addition of α-PD1 + α-MerTK mAbs to radiotherapy could alter the cell death to be more immunogenic and generate adaptive immune response via increasing the retention of TRM cells in the tumor islets of the abscopal tumors which was proven to play a major role in survival of non-small cell lung cancer patients.
Collapse
Affiliation(s)
- Mauricio S Caetano
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Ahmed I Younes
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | | | - Michael Quigley
- Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey
| | - Hari Menon
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Chan Gao
- Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey
| | - Thomas Spires
- Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey
| | - Timothy P Reilly
- Bristol-Myers Squibb (BMS), Redwood City, California and Princeton, New Jersey
| | - Alexandra P Cadena
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Taylor R Cushman
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.,University of Arizona College of Medicine-Phoenix, Phoenix, Arizona
| | - Jonathan E Schoenhals
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.,University of Texas Southwestern Medical School, Dallas, Texas
| | - Ailin Li
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.,Department of Radiation Oncology, First Hospital of China Medical University, China
| | - Quynh-Nhu Nguyen
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - Maria Angelica Cortez
- Department of Experimental Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas
| | - James W Welsh
- Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.
| |
Collapse
|
8
|
Shan W, Balog A, Nation A, Zhu X, Chen J, Cvijic ME, Geng J, Rizzo CA, Spires T, Attar RM, Obermeier M, Traeger S, Dai J, Zhang Y, Galella M, Trainor G, Vite GD, Gavai AV. [2.2.1]-Bicyclic sultams as potent androgen receptor antagonists. Bioorg Med Chem Lett 2016; 26:5707-5711. [PMID: 27836399 DOI: 10.1016/j.bmcl.2016.10.059] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2016] [Revised: 10/14/2016] [Accepted: 10/20/2016] [Indexed: 11/19/2022]
Abstract
This letter describes the discovery, synthesis, SAR, and biological activity of [2.2.1]-bicyclic sultams as potent antagonists of the androgen receptor. Optimization of the series led to the identification of compound 25, which displayed robust pharmacodynamic effects in rats after oral dosing.
Collapse
Affiliation(s)
- Weifang Shan
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States.
| | - Aaron Balog
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Andrew Nation
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Xiao Zhu
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Jing Chen
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Mary Ellen Cvijic
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Jieping Geng
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Cheryl A Rizzo
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Thomas Spires
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Ricardo M Attar
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Mary Obermeier
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Sarah Traeger
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Jun Dai
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Yingru Zhang
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Michael Galella
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - George Trainor
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Gregory D Vite
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| | - Ashvinikumar V Gavai
- Bristol-Myers Squibb Research and Development, PO Box 4000, Princeton, NJ 08543, United States
| |
Collapse
|
9
|
Balog A, Rampulla R, Martin GS, Krystek SR, Attar R, Dell-John J, DiMarco JD, Fairfax D, Gougoutas J, Holst CL, Nation A, Rizzo C, Rossiter LM, Schweizer L, Shan W, Spergel S, Spires T, Cornelius G, Gottardis M, Trainor G, Vite GD, Salvati ME. Discovery of BMS-641988, a Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. ACS Med Chem Lett 2015; 6:908-12. [PMID: 26288692 DOI: 10.1021/acsmedchemlett.5b00173] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2015] [Accepted: 06/19/2015] [Indexed: 11/29/2022] Open
Abstract
BMS-641988 (23) is a novel, nonsteroidal androgen receptor antagonist designed for the treatment of prostate cancer. The compound has high binding affinity for the AR and acts as a functional antagonist in vitro. BMS-641988 is efficacious in multiple human prostate cancer xenograft models, including CWR22-BMSLD1 where it displays superior efficacy relative to bicalutamide. Based on its promising preclinical profile, BMS-641988 was selected for clinical development.
Collapse
Affiliation(s)
- Aaron Balog
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Richard Rampulla
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Gregory S. Martin
- Albany Molecular Research Inc., 21 Corporate Circle, Albany, New York 12203, United States
| | - Stanley R. Krystek
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Ricardo Attar
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Janet Dell-John
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - John D. DiMarco
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - David Fairfax
- Albany Molecular Research Inc., 21 Corporate Circle, Albany, New York 12203, United States
| | - Jack Gougoutas
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Christian L. Holst
- Albany Molecular Research Inc., 21 Corporate Circle, Albany, New York 12203, United States
| | - Andrew Nation
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Cheryl Rizzo
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Lana M. Rossiter
- Albany Molecular Research Inc., 21 Corporate Circle, Albany, New York 12203, United States
| | - Liang Schweizer
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Weifang Shan
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Steven Spergel
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Thomas Spires
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Georgia Cornelius
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Marco Gottardis
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - George Trainor
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Gregory D. Vite
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| | - Mark E. Salvati
- Bristol Myers-Squibb Research and Development, Princeton, New Jersey 08543, United States
| |
Collapse
|
10
|
Xiao HY, Balog A, Attar RM, Fairfax D, Fleming LB, Holst CL, Martin GS, Rossiter LM, Chen J, Cvjic ME, Dell-John J, Geng J, Gottardis MM, Han WC, Nation A, Obermeier M, Rizzo CA, Schweizer L, Spires T, Shan W, Gavai A, Salvati ME, Vite G. Design and synthesis of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles as androgen receptor antagonists. Bioorg Med Chem Lett 2010; 20:4491-5. [PMID: 20584610 DOI: 10.1016/j.bmcl.2010.06.034] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2010] [Revised: 06/03/2010] [Accepted: 06/07/2010] [Indexed: 01/03/2023]
Abstract
A novel series of 4-[3,5-dioxo-11-oxa-4,9-diazatricyclo[5.3.1.0(2,6)]undec-4-yl]-2-trifluoromethyl-benzonitriles has been synthesized. The ability of these compounds to act as antagonists of the androgen receptor was investigated and several were found to have potent activity in vitro and in vivo.
Collapse
Affiliation(s)
- Hai-Yun Xiao
- Bristol-Myers Squibb Company, Research and Development, Princeton, NJ 08543-4000, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
SantaCruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, Kuskowski M, Hyman B, Hutton M, Ashe KH. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005; 309:476-81. [PMID: 16020737 PMCID: PMC1574647 DOI: 10.1126/science.1113694] [Citation(s) in RCA: 1409] [Impact Index Per Article: 74.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Neurofibrillary tangles (NFTs) are the most common intraneuronal inclusion in the brains of patients with neurodegenerative diseases and have been implicated in mediating neuronal death and cognitive deficits. Here, we found that mice expressing a repressible human tau variant developed progressive age-related NFTs, neuronal loss, and behavioral impairments. After the suppression of transgenic tau, memory function recovered, and neuron numbers stabilized, but to our surprise, NFTs continued to accumulate. Thus, NFTs are not sufficient to cause cognitive decline or neuronal death in this model of tauopathy.
Collapse
Affiliation(s)
| | - J. Lewis
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | - T. Spires
- Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | | | | | - M. Ingelsson
- Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | | | - M. DeTure
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | | | - E. McGowan
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | - C. Forster
- Department of Laboratory Medicine and Pathology
| | - M. Yue
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | - J. Orne
- Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | - C. Janus
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | | | - M. Kuskowski
- Geriatric Research, Education, and Clinical Center (GRECC), Minneapolis VA Hospital, Minneapolis, MN 55417, USA
| | - B. Hyman
- Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
| | - M. Hutton
- Department of Neuroscience, Mayo Clinic Jacksonville, Jacksonville, FL 32224, USA
| | - K. H. Ashe
- Department of Neurology
- Department of Neuroscience, and
- Graduate Program in Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA
- Geriatric Research, Education, and Clinical Center (GRECC), Minneapolis VA Hospital, Minneapolis, MN 55417, USA
- † To whom correspondence should be addressed. E-mail:
| |
Collapse
|